Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation
about
Fisetin lowers methylglyoxal dependent protein glycation and limits the complications of diabetesThe effects of diabetes on male fertility and epigenetic regulation during spermatogenesisMicroglial AGE-albumin is critical in promoting alcohol-induced neurodegeneration in rats and humansRAGE is a nucleic acid receptor that promotes inflammatory responses to DNADiabetic conditions promote binding of monocytes to vascular smooth muscle cells and their subsequent differentiationCo-expression of BirA with biotin bait achieves in vivo biotinylation of overexpressed stable N-glycosylated sRAGE in transgenic silkworms.LL-37 induced cystitis and the receptor for advanced glycation end-products (RAGE) pathway.Carboxylated N-glycans on RAGE promote S100A12 binding and signaling.Diabetic impairment of C-kit bone marrow stem cells involves the disorders of inflammatory factors, cell adhesion and extracellular matrix moleculesSoluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and agingDiabetes, related conditions, and dementia.Determinants of concentrations of N(ε)-carboxymethyl-lysine and soluble receptor for advanced glycation end products and their associations with risk of pancreatic cancerRAGE regulates immune cell infiltration and angiogenesis in choroidal neovascularization.The role of receptor for advanced glycation end products in airway inflammation in CF and CF related diabetes.Modeling the interaction between quinolinate and the receptor for advanced glycation end products (RAGE): relevance for early neuropathological processesChronic alcohol administration causes expression of calprotectin and RAGE altering the distribution of zinc ions in mouse testis.Association between the Advanced Glycosylation End Product-Specific Receptor Gene and Cardiovascular Death in Older MenAnti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus.Effects of RAGE Gene Polymorphisms on the Risk and Progression of Hepatocellular CarcinomaRAGE gene polymorphism and environmental factor in the risk of oral cancer.High-mobility group box-1 induces decreased brain-derived neurotrophic factor-mediated neuroprotection in the diabetic retina.RAGE is a key cellular target for Abeta-induced perturbation in Alzheimer's disease.Adherence to a Mediterranean diet and risk of incident cognitive impairment.The role of inflammatory processes in Alzheimer's disease.HMGB1 in development and diseases of the central nervous system.RAGE regulation and signaling in inflammation and beyond.Unlocking the biology of RAGE in diabetic microvascular complicationsCritical role of RAGE in lung physiology and tumorigenesis: a potential target of therapeutic intervention?Role of Toll-like receptors in diabetic nephropathy.The pathobiology of diabetic vascular complications--cardiovascular and kidney disease.Aggregation of the Inflammatory S100A8 Precedes Aβ Plaque Formation in Transgenic APP Mice: Positive Feedback for S100A8 and Aβ Productions.The self-association of HMGB1 and its possible role in the binding to DNA and cell membrane receptors.Neurodegeneration and Neuroinflammation in Diabetic Retinopathy: Potential Approaches to Delay Neuronal Loss.Beneficial effects of a novel RAGE inhibitor on early diabetic retinopathy and tactile allodynia.Skin autofluorescence relates to soluble receptor for advanced glycation end-products and albuminuria in diabetes mellitus.Receptor for advanced glycation end-products and World Trade Center particulate induced lung function loss: a case-cohort study and murine model of acute particulate exposureReceptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis.RAGE-Mediated Inflammation, Type 2 Diabetes, and Diabetic Vascular Complication.Spontaneous periodontitis development in diabetic rats involves an unrestricted expression of inflammatory cytokines and tissue destructive factors in the absence of major changes in commensal oral microbiota.Expression of high-mobility groups box-1/receptor for advanced glycation end products/osteopontin/early growth response-1 pathway in proliferative vitreoretinal epiretinal membranes.
P2860
Q21560804-0CB197E2-CE6B-4F01-BA27-299EB8A46573Q26998600-595AF9C7-EA55-4BDD-9A45-59CEF3672DE9Q27315179-CE00C133-5C2B-4FC3-81B9-4801E4562C1FQ27680115-F69B2528-0E18-45E4-BD47-606DBD8AEF98Q30433016-F7B2E54E-B6A7-4262-BD2E-62AA993B1A22Q33671771-0EA75539-FD80-48D7-A947-32630C0FD56FQ33690597-BB857473-E5FF-4BFC-AC6B-0C2A794B8647Q33890233-D84E36C1-334A-4F07-85DA-8024A2343641Q34044884-D7DC1F88-CFDA-4575-97D2-E4FBD17CDADDQ34094369-D6A77E96-86F5-4B77-A511-69CBDDBEC831Q34361375-B9D5020D-DE5C-4FBA-87A9-452FF51A2D0FQ34426525-C5624639-8F41-4EFB-9F33-851B5D3080D8Q35107593-E2254CC8-EAD1-4891-950C-ABFB8A922E51Q35160764-1A6AB9DA-2B4D-4C1F-AC76-E04A53F7CEC1Q35163077-DB667E06-6546-465D-83CA-B35807F4A0D1Q35228472-0B91E3DD-D75F-42FF-A3D8-B2D6B9DE3EA9Q35727237-F0888275-A313-4343-B6AA-50A784F66F9BQ35914764-82DC8BA5-C277-476E-B601-9344665A448CQ36153175-55DBCBDE-A1C8-4045-BDC9-D44664948D27Q36745763-010AC138-01C2-4392-805D-ECE5BB4916A3Q36900033-D91126B0-F5A9-43D2-A8B8-1DBD953CFACFQ36942363-8AE3EFD0-4B09-40A4-88FD-FBD12F5AF1D2Q37027499-27B9C80B-B6AD-4618-A845-9A2155AA85D2Q38005630-EF645048-4C4D-4226-BC49-F032031779E9Q38009688-3201F1B3-C140-4792-B453-B9AD0660D357Q38094691-87DAEDCB-D6F0-4C51-B0EC-31E3EF0DCC87Q38134924-86561CBF-E8E1-48D4-84DE-6C21723B6D2EQ38150990-7C1BD7EC-983B-4686-B53D-B80E7114CB55Q38184614-E07D3C86-94A3-483E-8100-320FDD650AD4Q38200957-D2854650-CF19-4F7D-93C1-0F97CED7EE41Q38774270-00F7E28A-6C2B-4231-8348-2CB3E6B8038DQ38777560-247410DF-CFD3-47CA-9994-B98B8274FD50Q38865936-35314101-BDD1-45EC-9F9E-8DD8A84DD398Q39727356-98240AC6-F369-4B0A-97F5-BE8AD21DE38AQ40509446-E62EDD8C-054B-4461-9373-5BF58E6C567BQ41571383-C94D3A6D-F509-45BB-90A7-89FF66A28802Q41871282-66C85388-B12C-4FF8-89B6-89261048C427Q41932557-B8FE6142-BD39-40E0-8EA4-D0E9ED95F574Q42073506-C75F8598-6099-4DD3-B8C4-790B839953DFQ42619210-234ABEBD-2FAB-400A-90D6-8E05EF4F183E
P2860
Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tempering the wrath of RAGE: a ...... degeneration, and inflammation
@en
Tempering the wrath of RAGE: a ...... egeneration, and inflammation.
@nl
type
label
Tempering the wrath of RAGE: a ...... degeneration, and inflammation
@en
Tempering the wrath of RAGE: a ...... egeneration, and inflammation.
@nl
prefLabel
Tempering the wrath of RAGE: a ...... degeneration, and inflammation
@en
Tempering the wrath of RAGE: a ...... egeneration, and inflammation.
@nl
P2093
P2860
P1433
P1476
Tempering the wrath of RAGE: a ...... degeneration, and inflammation
@en
P2093
Ann Marie Schmidt
Ravichandran Ramasamy
Shi Du Yan
Shi Fang Yan
P2860
P304
P356
10.1080/07853890902806576
P407
P577
2009-01-01T00:00:00Z